FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:257-265 July 25, 1996 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Hypertensive disorders are the most common medical complications of pregnancy and are an important cause of maternal and perinatal morbidity and mortality worldwide.¹ During normal pregnancy, systolic pressure changes little; however, diastolic pressure decreases by an average of 10 mm Hg early in gestation (13 to 20 weeks) and rises again to prepregnancy levels in the third trimester. The term "hypertension in pregnancy" describes a broad spectrum of conditions in which blood pressure varies widely. In reviewing the literature on this subject, one is faced with difficulties regarding the definitions and classifications used to categorize hypertension in pregnant women,^2,3,4,5,6 including . . . [Full Text of this Article]

Chronic Hypertension

Risks to the Mother and Fetus

Pharmacologic Treatment

Risks of Pharmacologic Treatment

Management of Chronic Hypertension

Gestational Hypertension

Preeclampsia

Pathophysiology

Risks of Preeclampsia to the Mother and Fetus

Management of Preeclampsia

            Mild Preeclampsia

            Severe Preeclampsia

Anticonvulsant Drug Therapy

Prevention of Preeclampsia

Conclusions

Source Information

From the Division of Maternal–Fetal Medicine, Department of Obstetrics and Gynecology, University of Tennessee, 853 Jefferson Ave., Rm. E102, Memphis, TN 38103, where reprint requests should be addressed to Dr. Sibai.

References

This article has been cited by other articles:

• Kolagasi, O., Sari, F., Akar, M., Sari, R. (2009). Normal Pregnancy and Healthy Child After Continued Exposure to Gliclazide and Ramipril During Pregnancy. The Annals of Pharmacotherapy 43: 147-149 [Abstract] [Full Text]  
• American Diabetes Association, (2009). Standards of Medical Care in Diabetes--2009. Diabetes Care 32: S13-S61 [Full Text]  
• American Diabetes Association, (2008). Standards of Medical Care in Diabetes--2008. Diabetes Care 31: S12-S54 [Full Text]  
• Tanaka, M., Jaamaa, G., Kaiser, M., Hills, E., Soim, A., Zhu, M., Shcherbatykh, I. Y., Samelson, R., Bell, E., Zdeb, M., McNutt, L.-A. (2007). Racial Disparity in Hypertensive Disorders of Pregnancy in New York State: A 10-Year Longitudinal Population-Based Study. AJPH 97: 163-170 [Abstract] [Full Text]  
• Gerhardt, M. A., Gunka, V. B., Miller, R. J. (2006). Hemodynamic Stability During Labor and Delivery With Continuous Epidural Infusion. JAOA: Journal of the American Osteopathic Association 106: 692-698 [Abstract] [Full Text]  
• Fernandez, A., Prieto, B., Escudero, A., Ladenson, J. H., Alvarez, F. V. (2005). A Monoclonal Antibody with Potential for Aiding Non-invasive Prenatal Diagnosis: Utility in Screening of Pregnant Women at Risk of Preeclampsia. J. Histochem. Cytochem. 53: 345-350 [Abstract] [Full Text]  
• James, P R., Nelson-Piercy, C. (2004). Management of hypertension before, during, and after pregnancy. Heart 90: 1499-1504 [Full Text]  
• Thadhani, R., Mutter, W. P., Wolf, M., Levine, R. J., Taylor, R. N., Sukhatme, V. P., Ecker, J., Karumanchi, S. A. (2004). First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia. J. Clin. Endocrinol. Metab. 89: 770-775 [Abstract] [Full Text]  
• Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L. Jr, Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T. Jr, Roccella, E. J., the National High Blood Pressure Education Program, (2003). Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206-1252 [Abstract] [Full Text]  
• Zhou, Y., McMaster, M., Woo, K., Janatpour, M., Perry, J., Karpanen, T., Alitalo, K., Damsky, C., Fisher, S. J. (2002). Vascular Endothelial Growth Factor Ligands and Receptors That Regulate Human Cytotrophoblast Survival Are Dysregulated in Severe Preeclampsia and Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome. Am. J. Pathol. 160: 1405-1423 [Abstract] [Full Text]  
• Ekbom, P., Damm, P., Feldt-Rasmussen, B., Feldt-Rasmussen, U., Molvig, J., Mathiesen, E. R. (2001). Pregnancy Outcome in Type 1 Diabetic Women With Microalbuminuria. Diabetes Care 24: 1739-1744 [Abstract] [Full Text]  
• Norwitz, E. R., Repke, J. T. (2000). Preeclampsia Prevention and Management. Reproductive Sciences 7: 21-36 [Abstract]  
• Magee, L A, Ornstein, M P, von Dadelszen, P (1999). Fortnightly review: Management of hypertension in pregnancy. BMJ 318: 1332-1336 [Full Text]  
• Holzgreve, W., Hahn, S. (1999). Novel Molecular Biological Approaches for the Diagnosis of Preeclampsia. Clin. Chem. 45: 451-452 [Full Text]  
• Sibai, B. M., Lindheimer, M., Hauth, J., Caritis, S., VanDorsten, P., Klebanoff, M., MacPherson, C., Landon, M., Miodovnik, M., Paul, R., Meis, P., Dombrowski, M., Thurnau, G., Roberts, J., McNellis, D., The National Institute of Child Health Human Devel, (1998). Risk Factors for Preeclampsia, Abruptio Placentae, and Adverse Neonatal Outcomes among Women with Chronic Hypertension. NEJM 339: 667-671 [Abstract] [Full Text]  
• (1997). The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157: 2413-2446 [Abstract]  
• Johnson, R. D., Sadovsky, Y., Graham, C., Anteby, E. Y., Polakoski, K. L., Huang, X., Nelson, D. M. (1997). The Expression and Activity of Prostaglandin H Synthase-2 Is Enhanced in Trophoblast from Women with Preeclampsia. J. Clin. Endocrinol. Metab. 82: 3059-3062 [Abstract] [Full Text]